In a new small trial of an experimental procedure, patients lost about 8% of their baseline weight and experienced a significant drop in their hunger.
The future of weight loss is looking more varied by the second. This week, scientists have reported the preliminary findings of a small trial testing out a novel, non-surgical procedure for obesity—one that works by burning part of the mucus-filled lining of the stomach. The patients in the trial lost about 8% of their baseline weight and experienced a significant drop in their hunger.
Related article: Fen-Phen Again? Why Ozempic and New Weight-Loss Drugs Are Different The findings are based on a very small sample size and have yet to be peer-reviewed, so they should be viewed with extra caution. Compared to other recently developed obesity treatments, particularly the emerging class of incretin-based medications such as semaglutide and tirzepatide , the weight loss effects of endoscopic mucosal ablation are also modest.
Hunger Digestive System Health Medical Pharma Semaglutide Bariatric Surgery Abdomen Obesity Gastroenterology Christopher Mcgowan Ghrelin Appetite Endocrinology Peptide Hormones Gizmodo
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Woman says she lost 60 pounds after undergoing experimental weight loss procedureThe minimally-invasive procedure targets ghrelin, the so-called hunger hormone.
Read more »
Endoscopic Procedure Targets 'Hunger Hormone' for Weight LossReducing the release of the 'hunger hormone' ghrelin through ablation of the gastric fundus lining shows promise for weight loss, a small study found.
Read more »
Promising endoscopic procedure burns stomach lining for weight lossAn innovative endoscopic procedure burns stomach lining to reduce ghrelin production, potentially leading to weight loss
Read more »
What To Know About New Minimally Invasive Weight Loss Procedure Gastric Mucosal AblationArianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
Read more »
Amgen scraps experimental weight loss pill, moves forward with injectionAmgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.
Read more »
Amgen scraps experimental weight loss pill, moves forward with injectionAmgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.
Read more »